Skip to main content

Animations

MJFF Publications

4461 - 4470 of 6255 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2020
  • 2020
  • 2020
  • 2019
  • 2020
  • 2020
  • 2021
  • Summary Details
    OPEN
    Title: Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
    Journal Name: Neurology and Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40120-021-00256-1
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
    Journal Name: Neurology and Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40120-021-00246-3
    Citation Count: 13
  • Summary Details
    OPEN
    Title: MicroRNA-7 Protects Against Neurodegeneration Induced by α-Synuclein Preformed Fibrils in the Mouse Brain
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s13311-021-01130-6
    Citation Count: 20
  • Summary Details
    OPEN
    Title: Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2020.04.032
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.04.002
    Citation Count: 46
  • Summary Details
    OPEN
    Title: The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.027
    Citation Count: 37
  • Summary Details
    OPEN
    Title: Parkinson's disease motor subtype changes during 20 years of follow-up
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2019.05.024
    Citation Count: 30
  • Summary Details
    OPEN
    Title: SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2020.04.005
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Variants in the Niemann–Pick type C gene NPC1 are not associated with Parkinson's disease
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2020.03.021
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.28745
    Citation Count: 18
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.